CompositionCarbamazepine (300 mg) SALT INFORMATIONCarbamazepine (300 mg) TYPICAL USAGE Epilepsy partial seizures. Primary generalised epilepsy or secondarily generalised forms of seizure with a tonic-clonic component. Mixed forms of epilepsy. Mania and prophylactic treatment in manic-depressive illness. Idiopathic trigeminal neuralgias and trigeminal neuralgia due to multiple sclerosis. Idiopathic glossopharyngeal neuralgia. Alcohol withdrawal syndrome. Diabetes insipidus centralis; polyuria and polydipsia of neurohormonal origin. Painful diabetic neuropathy. SIDE EFFECTS Proteinuria, skin rashes, stevens johnson syndrome, bradycardia, lymphadenopathy, coma, respiratory depression, aplastic anemia, stevens Johnson syndrome, hyperirritability, dizziness, vertigo, drowsiness, ataxia, nausea, vomiting, fever, blurred vision. DRUG INTERACTION Carbamazepine is known to interact with other drugs like alcohol, amitriptyline (HCl), amlodipine (besylate), artesunate, atracurium (besylate), betamethasone, bromazepam, bupropion (HCl), celecoxib, chloroquine, chlorpropamide, cimetidine (HCl), clarithromycin, clobazam, clonazepam, clozapine, cortisone (acetate), cyclosporin A, danazol, desmopressin (acetate). MECHANISM OF ACTION Carbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord.